IL2 and systemic lupus erythematosus: However, the increased IL-2 levels in SLE patients with active disease combined with our observation that Tregs may be refractory to further IL-2 stimulation (38), suggest that flaring SLE patients may not be the optimal target patient group to treat with exogenous IL-2.